Because AEAC has been shown to penetrate living cells, interact with Hsp70, and inhibit Hsp70 substrate-binding and refolding activities (and, therefore, to impair protective function of the chaperone), we suggest that the compound could reduce resistance of tumor cells to anti-cancer drugs. The gene discussed is HSPA1A; the disease is neoplasm.